Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Biotechnology

Healthcare
$0.90 +3.01%

+$0.06 today

Market cap
$54.28M
Beta
1.19
P/E (TTM)
-4.2
EPS (TTM)
-$0.45
52W Low $1.07High $6.18

Volume 1.45M

Average 2.13M

ALDX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Aldeyra Therapeutics, Inc.NASDAQ: ALDX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 60.32M shares rose 0.7% year over year, in line with the +1.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.7% toward the trailing-twelve-month pace of +1.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
60.32M+0.3% QoQ
Last fiscal yearDec 2025
60.06M+1.0% YoY
LTMMar 2026
60.16M+1.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.7%——
1 year+1.0%——
3-year CAGR+0.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
60.06M USD
Year-over-year change
+1.0%
4-year CAGR
+2.7%

Weighted Avg Shares vs competitors

How ALDX compares with its peers on the latest reported figures

  • ALDX's LTM Mar 2026 weighted avg shares of 60.16M shares is the 4th highest of the 11 companies compared; the peer median is 42.47M shares.
  • Its year-over-year change of +1.0% is the 9th highest of 10, against a peer median of +10.2%.
  • Over three fiscal years its annual growth of +0.9% compares with a peer median of +12.3%.
ALDX Competitors Peer median
Weighted Avg Shares for ALDX and competitors
Company Period LTM YoY 3-year CAGR
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
ACIUAC Immune S.A.LTM Mar 202699.9M -2.5%+6.4%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
CADLCandel Therapeutics, Inc.LTM Mar 202655.91M +73.2%+22.5%
KYTXKyverna Therapeutics, Inc.LTM Mar 202648.56M +12.5%+19.7%
GNLXGenelux CorporationLTM Mar 202636.38M +11.4%+14.8%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
AMRNAmarin Corporation plcLTM Mar 202620.78M +1.0%+1.1%
Peer median (excluding ALDX) 42.47M+10.2%+12.3%

Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development44.94M47.31M29.46M48.22M25.66M
Selling, General & Admin11.28M15.37M13.34M11.89M9.6M
Operating Expenses56.22M62.68M42.79M60.12M35.27M
Depreciation & Amortization264.18K258.71K262.78K249.62K251.99K
EBITDA(55.77M)(60.07M)(35.21M)(53.68M)(31.69M)
EBITDA Margin—————
Operating Income(56.22M)(62.68M)(42.79M)(60.12M)(35.27M)
Operating Margin—————
Interest Income185.36K2.35M7.32M6.19M3.32M
Interest Expense1.74M1.69M2.07M1.93M1.91M
Other Income / Expenses(1.56M)655.35K5.25M4.27M1.42M
Income Before Tax(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Net Margin—————
EPS (Basic)(1.07)(1.06)(0.64)(0.94)(0.56)
EPS (Diluted)(1.07)(1.06)(0.64)(0.94)(0.56)
Weighted Avg Shares54.04M58.41M58.94M59.48M60.06M
Weighted Avg Shares (Diluted)54.04M58.41M58.94M59.48M60.06M

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.